The government has reached an agreement with Roche Products to supply 15,000 doses of the COVID-19 antibody-based therapy Ronapreve.
Mr Hunt said the intravenous treatment given in the early stages of infection provides a 70 per cent reduction in the likelihood of someone being hospitalised or dying.
“These doses are to be in Australia during the course of October and subject to TGA approval,” he told reporters in Canberra on Sunday.
